Denali Therapeutics: Leerink Partners cuts target price to $30 from $35
DNLI•Leerink Partners cut its target price for Denali Therapeutics to $30 from $35.
Related News
A10 Networks schedules third-quarter 2026 results release, conference call
ATEN•
Hyperfine Q3 sales $6 million
HYPR•
Lightspeed to host fiscal Q2 2027 results conference call and webcast
LSPD•
Saratoga Investment Corp: B. Riley cuts target price to $20 from $22
SAR•
Eni CCUS installs Douglas platform for Liverpool Bay carbon storage project in UK
E•